Serplulimab + chemotherapy

DRUG2 trials

Sponsors

Fudan University, Zhejiang University

Conditions

Fasting, IntermittentLocally Advanced Rectal CarcinomaResectable Stage II-IIIa Squamous NSCLCpMMR/MSS

Phase 2

Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC

RecruitingNCT07398937

Fudan UniversityResectable Stage II-IIIa Squamous NSCLC

Start: 2026-02-05End: 2029-12-31Target: 116Updated: 2026-02-10

16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer

Not yet recruitingNCT07779694

Zhejiang UniversityFasting, Intermittent, Locally Advanced Rectal Carcinoma, pMMR/MSS

Start: 2026-10-01End: 2029-12-31Target: 51Updated: 2026-09-08